Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma
Cancers · 23.06.2026 · 18 (13) · 2032
DOI: 10.3390/cancers18132032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 23.06.2026. Verfasst von Katharina van der Weg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
BCMA-targeted Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of Relapsed/Refractory Multiple Myeloma (RRMM). However, the disease is not curable and progression after CAR T-cell treatment remains a challenge. Clonal hematopoiesis, specifically mutations in the DNA damage response gene PPM1D, has been linked to therapy resistance and inferior survival in lymphoma patients undergoing cellular therapy. The impact of PPM1D mutations on MM patient outcome after CAR T-cell therapy remains undefined.
Methods
We conducted a retrospective single-center study of 83 patients with RRMM patients treated with idecabtagene vicleucel or ciltacabtagene autoleucel between 2022 and 2025. Next-generation sequencing was performed on peripheral blood mononuclear cells collected prior to CAR T-cell infusion to identify PPM1D exon 6 mutations (variant allele frequency > 0.01). We analyzed associations between mutational status, clinical characteristics, toxicity, and survival.
Results
PPM1D mutations were detected in 14.5% (12/83) of patients. PPM1D-mutated patients had fewer prior autologous stem cell transplantation compared to wild-type patients (50% vs. 82%, p = 0.02) and presented more advanced disease burden and adverse prognostic features (R-ISS stage III 58% vs. 20%, p = 0.05). Notably, PPM1D status did not impact initial efficacy; complete remission rates were comparable between groups (67% vs. 69%). However, PPM1D mutations were significantly associated with inferior progression-free survival (PFS) (median PFS: 6 months vs. 16 months, p = 0.04). Regarding toxicity, the mutated subgroup exhibited significantly higher rates of grade ≥2 cytokine release syndrome and a trend toward increased neurotoxicity (25% vs. 7%).
Conclusions
PPM1D clonal hematopoiesis is frequent in RRMM and despite deep initial responses, patients harboring PPM1D mutations face a significantly higher risk of early relapse. PPM1D mutations may serve as a biomarker for poor durability of response and should be further evaluated in larger, prospective trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
- Department of Hematology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
- Department of Clinical Chemistry, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
- Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
ORCID-Profile: Katharina van der Weg, Martina Bertschinger, Ulrike Bacher, Henning Nilius, Katja Seipel, Thomas Pabst
Zitieren
APA
van der Weg, K., Bertschinger, M., Bacher, U., Hoffmann, M., Nilius, H., Seipel, K., & Pabst, T. (2026). Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma. Cancers, 18(13), 2032. https://doi.org/10.3390/cancers18132032
Vancouver
van der Weg K, Bertschinger M, Bacher U, Hoffmann M, Nilius H, Seipel K, et al. Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma. Cancers. 2026;18(13):2032. doi:10.3390/cancers18132032
BibTeX
@article{vanderWeg2026,
author = {van der Weg, Katharina and Bertschinger, Martina and Bacher, Ulrike and Hoffmann, Michele and Nilius, Henning and Seipel, Katja and Pabst, Thomas},
title = {Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2032},
doi = {10.3390/cancers18132032}
}
EUVIMED